Keith Stewart, MB ChB

Keith Stewart is a Hematologist/Internist at Mayo Clinic, Phoenix, Arizona. He completed Residency in Internal Medicine from Queen's University and Fellowship in Hematology from University of Toronto and Fellowship in MRC Research from New England Medical Center, Boston, Massachusetts. He is also associated with Mayo Clinicexternal link, opens in a new tab, Rochester, Minnesota.

Dr. Keith Stewart conducts translational research in multiple myeloma which includes both basic and clinical research to identify novel targets for therapy in multiple myeloma.

Dr. Stewart's research is supported by the National Cancer Institute, Multiple Myeloma Research Foundation, and Leukemia & Lymphoma Society, as well as by partnerships with the pharmaceutical industry for clinical trials. His main interest lies in areas like myeloma, Waldenstrom's macroglobulinemia, amyloidosis, drug development, clinical trials, correlative biology and genomics.

Representative Publications:

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4external link, opens in a new tab

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myelomaexternal link, opens in a new tab

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenanceexternal link, opens in a new tab

Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestryexternal link, opens in a new tab